Standout Papers

NTRK gene fusions as nove... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
    2016 421 citations Alessio Amatu, Andrea Sartore‐Bianchi et al. ESMO Open profile →

Immediate Impact

7 from Science/Nature 63 hit
Sub-graph 1 of 21

Citing Papers

Synthetic Biology in Natural Product Biosynthesis
2025 Hit
New immune cell engagers for cancer immunotherapy
2024 Hit
1 intermediate paper

Works of Alessio Amatu being referenced

Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
2022

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alessio Amatu 1.5k 822 618 595 569 80 2.3k
Katia Bencardino 1.8k 1.2× 804 1.0× 588 1.0× 591 1.0× 666 1.2× 77 2.3k
J. L. Misset 2.1k 1.4× 1.0k 1.3× 565 0.9× 431 0.7× 438 0.8× 63 3.0k
In‐Gu Do 1.0k 0.7× 686 0.8× 515 0.8× 1.1k 1.8× 422 0.7× 97 2.5k
Peter J. Hosein 1.6k 1.1× 651 0.8× 557 0.9× 285 0.5× 323 0.6× 110 2.3k
Andreas Schalhorn 1.8k 1.2× 811 1.0× 601 1.0× 617 1.0× 255 0.4× 93 3.0k
M Francoual 1.5k 1.0× 685 0.8× 327 0.5× 728 1.2× 305 0.5× 60 2.2k
Soomin Ahn 1.2k 0.8× 639 0.8× 523 0.8× 763 1.3× 371 0.7× 132 2.6k
Thomas A. Abrams 1.4k 0.9× 665 0.8× 353 0.6× 697 1.2× 367 0.6× 84 2.4k
D. J. Richel 1.6k 1.1× 893 1.1× 512 0.8× 726 1.2× 312 0.5× 38 2.6k
Oronzo Brunetti 1.5k 1.0× 520 0.6× 776 1.3× 1.1k 1.8× 262 0.5× 124 3.0k

All Works

Loading papers...

Rankless by CCL
2026